DKSH has entered into a partnership with Pfizer to commercialize and distribute its anti‑infective therapies, marking a significant milestone in strengthening Malaysia’s access to vital, life‑saving treatments. This collaboration builds on DKSH’s existing partnerships with Pfizer in multiple markets in Southeast Asia further strengthening Pfizer’s footprint and execution capabilities across the region.
Petaling Jaya, Malaysia, February 3, 2026 – DKSH Business Unit Healthcare, a leading partner for companies seeking to grow their healthcare business in Asia and beyond, has entered into a strategic partnership with Pfizer (Malaysia) Sdn. Bhd., a subsidiary of the global pharmaceutical company Pfizer Inc., to provide comprehensive distribution, sales, and marketing services for Pfizer’s anti-infectives portfolio throughout Malaysia.
Pfizer’s anti-infectives portfolio comprises a strong mix of established therapies that play a vital role in treating moderate to severe infections, alongside newer, clinically robust antimicrobial treatments. Under this collaboration, DKSH will manage end-to-end commercial operations, including warehousing, nationwide distribution, and integrated sales and marketing support across all healthcare channels. By combining Pfizer’s scientific innovation with DKSH’s extensive commercial infrastructure and deep market expertise, the collaboration aims to significantly broaden access to essential antimicrobial therapies across the market. Building on DKSH’s existing partnerships with Pfizer across several markets in Southeast Asia such as Thailand, Taiwan, and Laos, this collaboration highlights both companies’ continued focus on improving access to healthcare solutions and driving sustainable growth in fast-growing markets.
Deborah Seifert, Cluster Lead - Malaysia, Indonesia, Singapore, Philippines at Pfizer (Malaysia) Sdn. Bhd. commented: “At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We are pleased to continue to work with DKSH as a strategic partner to expand access to our anti-infective portfolio, supporting healthcare professionals with reliable, high-quality treatment options that address serious infectious diseases.”
Sandeep Tewari, Vice President, Healthcare and Head, Country Leadership, Malaysia, DKSH, added: “This partnership reflects our shared commitment to improving patient outcomes by ensuring timely access to innovative and essential antimicrobial therapies. By combining Pfizer’s strong scientific leadership with DKSH’s proven commercial capabilities and extensive distribution network, we aim to deliver greater value to healthcare providers and patients nationwide, providing better healthcare for all.”
Together, DKSH Malaysia and Pfizer are committed to strengthening infection management in Malaysia and advancing patient care through timely access to essential therapies.
About Pfizer
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. The company strives to set the standard for quality, safety, and value in the discovery, development, and manufacture of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that address some of the world’s most challenging diseases. Consistent with its responsibility as one of the world’s premier innovative biopharmaceutical companies, Pfizer collaborates with healthcare providers, governments, and local communities to support and expand access to reliable, affordable healthcare worldwide, making a meaningful difference for all who rely on its work. www.pfizer.com.my
About DKSH
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products and medical devices. With around 7,940 specialists, the Business Unit generated net sales of CHF 5.7 billion in 2024. www.dksh.com/hec